Bristol-Myers Squibb will now challenge its rival, MSD's Keytruda, in second line lung cancer treatment in England after it agreed a 'managed access' deal with NICE.
The charity Cancer Research UK has joined with Biotecnol to begin early-stage clinical trials of a new kind of cancer immunotherapy in solid tumours, including lung cancers.
While ASCO often showcases the benefits of new cancer therapies, it was a well-established drug that proved to be a talking point at this year’s conference in Chicago.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
